Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study-Reference-Cited by-同舟云学术

Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study

Published:2023-08-31 Issue:17 Volume:15 Page:4348
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Tanaka Kazunari¹,Tsuji Kunihiko¹^ORCID,Hiraoka Atsushi²^ORCID,Tada Toshifumi³,Hirooka Masashi⁴^ORCID,Kariyama Kazuya⁵^ORCID,Tani Joji⁶,Atsukawa Masanori⁷,Takaguchi Koichi⁸,Itobayashi Ei⁹,Fukunishi Shinya¹⁰,Ishikawa Toru¹¹,Tajiri Kazuto¹²^ORCID,Ochi Hironori¹³,Toyoda Hidenori¹⁴^ORCID,Ogawa Chikara¹⁵^ORCID,Nishimura Takashi¹⁶^ORCID,Hatanaka Takeshi¹⁷^ORCID,Kakizaki Satoru¹⁸^ORCID,Shimada Noritomo¹⁹,Kawata Kazuhito²⁰^ORCID,Naganuma Atsushi²¹^ORCID,Kosaka Hisashi²²^ORCID,Matono Tomomitsu²³,Kuroda Hidekatsu²⁴^ORCID,Yata Yutaka²⁵,Ohama Hideko²^ORCID,Tada Fujimasa²,Nouso Kazuhiro⁵^ORCID,Morishita Asahiro⁶^ORCID,Tsutsui Akemi⁸,Nagano Takuya⁸,Itokawa Norio⁷,Okubo Tomomi⁷,Arai Taeang⁷,Yokohama Keisuke¹⁰,Nishikawa Hiroki¹⁰,Imai Michitaka¹¹,Koizumi Yohei⁴,Nakamura Shinichiro³^ORCID,Iijima Hiroko¹⁶,Kaibori Masaki²²^ORCID,Hiasa Yoichi⁴^ORCID,Kumada Takashi²⁶

Affiliation:

1. Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo 006-8555, Japan

2. Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama 790-0024, Japan

3. Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji 670-8540, Japan

4. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon 791-0295, Japan

5. Department of Hepatology, Okayama City Hospital, Okayama 700-0962, Japan

6. Department of Gastroenterology and Hepatology, Kagawa University, Kagawa 761-0795, Japan

7. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan

8. Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu 760-8557, Japan

9. Department of Gastroenterology, Asahi General Hospital, Asahi 289-2511, Japan

10. Department of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan

11. Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata 950-1104, Japan

12. Department of Gastroenterology, Toyama University Hospital, Toyama 930-0194, Japan

13. Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama 790-8524, Japan

14. Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki 503-8502, Japan

15. Department of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu 760-0017, Japan

16. Department of Gastroenterology and Hepatology, Hyogo Medical University, Nishinomiya 663-8501, Japan

17. Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi 371-0821, Japan

18. Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki 370-0829, Japan

19. Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa 277-0863, Japan

20. Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu 565-0871, Japan

21. Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki 370-0829, Japan

22. Department of Surgery, Kansai Medical University, Hirakata 573-1010, Japan

23. Department of Hepatology, St. Mary’s Hospital, Himeji 670-0801, Japan

24. Division of Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Morioka 020-8505, Japan

25. Department of Gastroenterology, Hanwa Memorial Hospital, Osaka 558-0041, Japan

26. Department of Nursing, Gifu Kyoritsu University, Ogaki 503-8550, Japan

Abstract

Aim: This study aimed to evaluate the ability of a previously reported tumor marker (TM) score involving alpha-fetoprotein (AFP), fucosylated AFP (AFP-L3), and des gamma-carboxy prothrombin (DCP) as TMs in predicting the prognosis and therapeutic efficacy in hepatocellular carcinoma (HCC) patients administered atezolizumab plus bevacizumab (Atez/Bev) as first-line treatment. Materials/Methods: The study period covered September 2020 to December 2022 and involved 371 HCC patients treated with Atez/Bev. The values of the TMs AFP, AFP-L3, and DCP were measured upon introducing Atez/Bev. Elevations in the values of AFP (≥100 ng/mL), AFP-L3 (≥10%), and DCP (≥100 mAU/mL) were considered to indicate a positive TM. The number of positive TMs was summed up and used as the TM score, as previously proposed. Hepatic reserve function was assessed using the modified albumin–bilirubin grade (mALBI). Predictive values for prognosis were evaluated retrospectively. Results: A TM score of 0 was shown in 81 HCC patients (21.8%), 1 in 110 (29.6%), 2 in 112 (29.9%), and 3 in 68 (18.3%). The median overall survival (OS) times for TM scores 0, 1, 2, and 3 were not applicable [NA] (95% CI NA-NA), 24.0 months (95% CI 17.8-NA), 16.7 months (95% CI 17.8-NA), and NA (95% CI 8.3-NA), respectively (p < 0.001). The median progression-free survival (PFS) times for TM scores 0, 1, 2, and 3 were 16.5 months (95% CI 8.0-not applicable [NA]), 13.8 months (95% CI 10.6–21.3), 7.7 months (95% CI 5.3–8.9), and 5.8 months (95% CI 3.0–7.6), respectively (p < 0.001). OS was well stratified in mALBI 1/2a and mALBI 2a/2b. PFS was well stratified in mALBI 2a/2b, but not in mALBI 1/2a. Conclusions: The TM score involving AFP, AFP-L3, and DCP as TMs was useful in predicting the prognosis and therapeutic efficacy in terms of OS and PFS in HCC patients administered Atez/Bev as first-line treatment.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

https://www.mdpi.com/2072-6694/15/17/4348/pdf

Reference42 articles.

1. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma;Finn;N. Engl. J. Med.,2020

2. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma;Cheng;J. Hepatol.,2022

3. Prognosis of hepatocellular carcinoma: The BCLC staging classification;Llovet;Semin. Liver Dis.,1999

4. (1998). A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology, 28, 751–755.

5. Prognostic staging system for hepatocellular carcinoma (CLIP score): Its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score);Kudo;J. Gastroenterol.,2003

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma;Current Oncology;2024-07-26

2. Clinical features of patients with hepatocellular carcinoma treated with radiofrequency ablation therapy: developing a simple score to determine the need for immune-adjuvant therapy;Clinical Journal of Gastroenterology;2024-03-26